Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) ·
Folvite; mostly generic (1) ·
Mag-Ox, Slow-Mag, MagCitrate, Milk of Magnesia (hydroxide); IV sulfate generic (1) ·
Many OTC and Rx; Nascobal (intranasal); generic injection (1) ·
Stromectol (oral, generic), Sklice (lice, topical), Soolantra (rosacea, topical 1%) (1) ·
Sunosi (1) ·
Tums, Caltrate, Os-Cal, Citracal; many generics (1)
hydroxide)]] (1) ·
Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) ·
torsades)]] (1) ·
wake-promoting agent (1) ·
[[:Category:Antacids|Antacid (carbonate)]] (1) ·
[[:Category:Antacids|Antacid (hydroxide)]] (1) ·
[[:Category:Antiarrhythmics|Antiarrhythmic (IV sulfate (1) ·
[[:Category:Antiparasitics|Antiparasitic]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (2) ·
[[:Category:Calcium_supplements|Calcium supplement]] (1) ·
[[:Category:Electrolyte_replacements|Electrolyte replacement]] (2) ·
[[:Category:Hematinics|Hematinic]] (3) ·
[[:Category:Iron_supplements|Iron supplement]] (1) ·
[[:Category:Macrocyclic_lactones|Macrocyclic lactone (avermectin)]] (1) ·
[[:Category:Osmotic_laxatives|Osmotic laxative (citrate (1) ·
[[:Category:Vitamins|Vitamin]] (2)
None (5) ·
Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) ·
'"`UNIQ--vote-00001302-QINU`"' Renally cleared; accumulation in advanced CKD can produce neuromuscular and cardiac depression. Hypomagnesemia frequently co-exists with hypokalemia and is often the reason refractory potassium loss does not correct until magnesium is repleted. (1)
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) ·
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1) ·
'"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"' (1) ·
'"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"' (1) ·
'"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"' (1)
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) ·
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) ·
Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia (1) ·
Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1) ·
Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months (1)
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) ·
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) ·
3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra) (1) ·
325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx (1) ·
75 mg, 150 mg tablets (1) ·
Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV (1) ·
Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules (1)
1 mg/d typical Rx; higher in specific indications (1) ·
150 mg/d (1) ·
Indication-specific; renal clearance limits tolerable cumulative dosing (1) ·
No strict ceiling; water-soluble vitamin, low toxicity (1) ·
Single 200-400 mcg/kg per dose for systemic indications (1) ·
~200 mg elemental iron/d typical practical limit (1) ·
~2500 mg elemental/d combined diet + supplements (chronic; UL) (1)
Acute: minutes (IV); chronic: bone effect over months (1) ·
Hematologic response within days (1) ·
Hours to days (1) ·
Oral: hours; IV: minutes (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) ·
Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks (1) ·
~30-60 min (1)
N/A (incorporated into hemoglobin and tissue stores) (1) ·
Not meaningfully described (electrolyte) (1) ·
Not meaningfully described (electrolyte; renally cleared) (1) ·
~0.5 hours plasma; tissue retention longer (1) ·
~16-18 hours'"`UNIQ--ref-00001092-QINU`"' (1) ·
~6 days (plasma); hepatic stores last 3-5 years (1) ·
~7.1 hours (1)
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate) (1) ·
Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) (1) ·
High (oral) (1) ·
Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% (1) ·
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) ·
~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' (1) ·
~95% (1)
IV sulfate is the cornerstone of eclampsia/preeclampsia management; oral replacement also safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; pregnancy exposure registry available (1) ·
Limited data; risk-benefit case by case; pregnancy is not a strict contraindication in WHO mass drug administration programs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy; needs higher in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely used; iron requirements rise substantially in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) ·
OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) ·
OTC (oral salts) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC (oral supplements) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) ·
OTC in US (1) ·
Rx, Schedule IV (US) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1)
Showing below up to 7 results in range #1 to #7.


